Pr Gerald Raverot

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6949312/publications.pdf

Version: 2024-02-01

152 papers	8,134 citations	50276 46 h-index	54911 84 g-index
160 all docs	160 docs citations	160 times ranked	5442 citing authors

#	Article	IF	Citations
1	A new prognostic clinicopathological classification of pituitary adenomas: a multicentric caseâ€“control study of 410 patients with 8Âyears post-operative follow-up. Acta Neuropathologica, 2013, 126, 123-135.	7.7	395
2	European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. European Journal of Endocrinology, 2018, 178, G1-G24.	3.7	387
3	Clinical Characteristics and Therapeutic Responses in Patients with Germ-LineAIPMutations and Pituitary Adenomas: An International Collaborative Study. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E373-E383.	3.6	323
4	Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes and Endocrinology,the, 2014, 2, 875-884.	11.4	309
5	Aryl Hydrocarbon Receptor-Interacting Protein Gene Mutations in Familial Isolated Pituitary Adenomas: Analysis in 73 Families. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1891-1896.	3.6	283
6	From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocrine-Related Cancer, 2017, 24, C5-C8.	3.1	262
7	Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement. Pituitary, 2017, 20, 489-498.	2.9	233
8	Ketoconazole in Cushing's Disease: Is It Worth a Try?. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1623-1630.	3.6	231
9	Temozolomide Treatment in Aggressive Pituitary Tumors and Pituitary Carcinomas: A French Multicenter Experience. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 4592-4599.	3.6	202
10	Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. European Journal of Endocrinology, 2018, 178, 265-276.	3.7	196
11	Sox3 Is Required for Gonadal Function, but Not Sex Determination, in Males and Females. Molecular and Cellular Biology, 2003, 23, 8084-8091.	2.3	168
12	A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. Endocrine-Related Cancer, 2007, 14, 887-900.	3.1	146
13	Prognostic Factors in Prolactin Pituitary Tumors: Clinical, Histological, and Molecular Data from a Series of 94 Patients with a Long Postoperative Follow-Up. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1708-1716.	3.6	144
14	Sox3 expression in undifferentiated spermatogonia is required for the progression of spermatogenesis. Developmental Biology, 2005, 283, 215-225.	2.0	142
15	Altered MicroRNA Expression Profile in Human Pituitary GH Adenomas: Down-Regulation of miRNA Targeting HMGA1, HMGA2, and E2F1. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1128-E1138.	3.6	136
16	Management of clinically non-functioning pituitary adenoma. Annales D'Endocrinologie, 2015, 76, 239-247.	1.4	136
17	Predicting Visual Outcome After Treatment of Pituitary Adenomas With Optical Coherence Tomography. American Journal of Ophthalmology, 2009, 147, 64-70.e2.	3.3	135
18	Evidence of improved surgical outcome following endoscopy for nonfunctioning pituitary adenoma removal. Neurosurgical Focus, 2011, 30, E11.	2.3	126

#	Article	IF	Citations
19	Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clinical Endocrinology, 2012, 76, 769-775.	2.4	125
20	How to Classify Pituitary Neuroendocrine Tumors (PitNET)s in 2020. Cancers, 2020, 12, 514.	3.7	123
21	Hypothalamo-pituitary sarcoidosis: a multicenter study of 24 patients. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 981-995.	0.5	116
22	Risk of Recurrence in Pituitary Neuroendocrine Tumors: A Prospective Study Using a Five-Tiered Classification. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3368-3374.	3.6	112
23	Influence ofSHBGGene Pentanucleotide TAAAA Repeat and D327N Polymorphism on Serum Sex Hormone-Binding Globulin Concentration in Hirsute Women. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 917-924.	3.6	109
24	Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. European Journal of Endocrinology, 2017, 176, 769-777.	3.7	107
25	Sex hormone-binding globulin gene expression in the liver: Drugs and the metabolic syndrome. Molecular and Cellular Endocrinology, 2010, 316, 53-59.	3.2	100
26	Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 467 35-43.	3.7	94
27	New targeted therapies in pituitary carcinoma resistant to temozolomide. Pituitary, 2012, 15, 37-43.	2.9	87
28	Macroprolactinomas in Children and Adolescents: Factors Associated With the Response to Treatment in 77 Patients. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1177-1186.	3.6	83
29	T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocrine-Related Cancer, 2016, 23, 871-881.	3.1	82
30	Nuclear receptors Sf1 and Dax1 function cooperatively to mediate somatic cell differentiation during testis development. Development (Cambridge), 2005, 132, 2415-2423.	2.5	81
31	Clinical Characteristics and Outcome of Acromegaly Induced by Ectopic Secretion of Growth Hormone-Releasing Hormone (GHRH): A French Nationwide Series of 21 Cases. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2093-2104.	3.6	81
32	MANAGEMENT OF ENDOCRINE DISEASE: Clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies. European Journal of Endocrinology, 2014, 170, R121-R132.	3.7	81
33	Clinical Biology of the Pituitary Adenoma. Endocrine Reviews, 2022, 43, 1003-1037.	20.1	81
34	Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies. Human Pathology, 2014, 45, 71-77.	2.0	79
35	miR-23b and miR-130b expression is downregulated in pituitary adenomas. Molecular and Cellular Endocrinology, 2014, 390, 1-7.	3.2	78
36	Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. Endocrine-Related Cancer, 2015, 22, 169-177.	3.1	78

#	Article	IF	Citations
37	Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth. European Journal of Endocrinology, 2015, 172, 791-801.	3.7	76
38	Mitotane Has an Estrogenic Effect on Sex Hormone-Binding Globulin and Corticosteroid-Binding Globulin in Humans. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2165-2170.	3.6	75
39	Acromegaly induced by ectopic secretion of GHRH: A review 30 years after GHRH discovery. Annales D'Endocrinologie, 2012, 73, 497-502.	1.4	64
40	Giant prolactinomas in women. European Journal of Endocrinology, 2014, 170, 31-38.	3.7	64
41	Ectopic ACTH Syndrome in Children and Adolescents. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1213-1222.	3.6	63
42	Pituitary Involvement in Granulomatosis With Polyangiitis. Medicine (United States), 2015, 94, e748.	1.0	61
43	Aggressive pituitary tumours and pituitary carcinomas. Nature Reviews Endocrinology, 2021, 17, 671-684.	9.6	60
44	Aggressive pituitary tumours and carcinomas: two sides of the same coin?. European Journal of Endocrinology, 2018, 178, C7-C9.	3.7	54
45	Signs and symptoms of acromegaly at diagnosis: the physicianâ€™s and the patientâ€™s perspectives in the ACRO-POLIS study. Endocrine, 2019, 63, 120-129.	2.3	51
46	Immunotherapy in Corticotroph and Lactotroph Aggressive Tumors and Carcinomas: Two Case Reports and a Review of the Literature. Journal of Personalized Medicine, 2020, 10, 88.	2.5	49
47	HMGA1-pseudogene expression is induced in human pituitary tumors. Cell Cycle, 2015, 14, 1471-1475.	2.6	48
48	Integrated Genomic Profiling Identifies Loss of Chromosome 11p Impacting Transcriptomic Activity in Aggressive Pituitary PRL Tumors. Brain Pathology, 2011, 21, 533-543.	4.1	46
49	Downregulation of miR-410 targeting the cyclin B1 gene plays a role in pituitary gonadotroph tumors. Cell Cycle, 2015, 14, 2590-2597.	2.6	46
50	Hepatic safety of ketoconazole in Cushingâ€™s syndrome: results of a Compassionate Use Programme in France. European Journal of Endocrinology, 2018, 178, 447-458.	3.7	46
51	The Microenvironment of Pituitary Tumorsâ€”Biological and Therapeutic Implications. Cancers, 2019, 11, 1605.	3.7	44
52	Clinical, Pathological, and Molecular Factors of Aggressiveness in Lactotroph Tumours. Neuroendocrinology, 2019, 109, 70-76.	2.5	44
53	Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma. Clinical Endocrinology, 2009, 70, 588-592.	2.4	42
54	Sex-Related Differences in Lactotroph Tumor Aggressiveness Are Associated With a Specific Gene-Expression Signature and Genome Instability. Frontiers in Endocrinology, 2018, 9, 706.	3.5	40

#	Article	IF	Citations
55	Establishment of revised diagnostic cut-offs for adrenal laboratory investigation using the new Roche Diagnostics ElecsysÂ® Cortisol II assay. Annales D'Endocrinologie, 2016, 77, 620-622.	1.4	39
56	MicroRNAs in pituitary tumors. Molecular and Cellular Endocrinology, 2017, 456, 51-61.	3.2	39
57	Triple-A syndrome: a wide spectrum of adrenal dysfunction. European Journal of Endocrinology, 2018, 178, 199-207.	3.7	38
58	Pasireotide: A potential therapeutic alternative for resistant prolactinoma. Annales D'Endocrinologie, 2019, 80, 84-88.	1.4	38
59	Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study. European Journal of Endocrinology, 2020, 182, 583.	3.7	36
60	Emerging and Novel Treatments for Pituitary Tumors. Journal of Clinical Medicine, 2019, 8, 1107.	2.4	34
61	A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors. Clinical Cancer Research, 2020, 26, 957-969.	7.0	34
62	Deregulation of miR-183 and KIAA0101 in Aggressive and Malignant Pituitary Tumors. Frontiers in Medicine, 2015, 2, 54.	2.6	33
63	Silent somatotroph tumour revisited from a study of 80 patients with and without acromegaly and a review of the literature. European Journal of Endocrinology, 2017, 176, 195-201.	3.7	33
64	Definition and diagnosis of aggressive pituitary tumors. Reviews in Endocrine and Metabolic Disorders, 2020, 21, 203-208.	5.7	33
65	Aggressive Silent GH Pituitary Tumor Resistant to Multiple Treatments, Including Temozolomide. Cancer Investigation, 2013, 31, 190-196.	1.3	32
66	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. Journal of the Endocrine Society, 2021, 5, bvaa205.	0.2	31
67	Frequency and Incidence of Carney Complex Manifestations: A Prospective Multicenter Study With a Three-Year Follow-Up. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e436-e446.	3.6	30
68	Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinicianâ€™s questions. Reviews in Endocrine and Metabolic Disorders, 2020, 21, 243-251.	5.7	30
69	A Prognostic Clinicopathologic Classification of Pituitary Endocrine Tumors. Endocrinology and Metabolism Clinics of North America, 2015, 44, 11-18.	3.2	29
70	Ommaya Reservoir System for the Treatment of Cystic Craniopharyngiomas: Surgical Results in a Series of 11 Adult Patients and Review of the Literature. World Neurosurgery, 2019, 132, e869-e877.	1.3	29
71	Prognostic factors of regrowth in nonfunctioning pituitary tumors. Pituitary, 2018, 21, 176-182.	2.9	28
72	Aggressive Pituitary Adenomas and Carcinomas. Endocrinology and Metabolism Clinics of North America, 2020, 49, 505-515.	3.2	28

#	Article	IF	Citations
73	Proliferation markers of human pituitary tumors: Contribution of a genome-wide transcriptome approach. Molecular and Cellular Endocrinology, 2010, 326, 30-39.	3.2	27
74	Predicting early post-operative remission in pituitary adenomas: evaluation of the modified knosp classification. Pituitary, 2019, 22, 467-475.	2.9	27
75	Current status and treatment modalities in metastases to the pituitary: a systematic review. Journal of Neuro-Oncology, 2020, 146, 219-227.	2.9	27
76	Anti-PD1 and Anti-PDL1-Induced Hypophysitis: A Cohort Study of 17 Patients with Longitudinal Follow-Up. Journal of Clinical Medicine, 2020, 9, 3280.	2.4	27
77	Non-functioning pituitary macro-incidentalomas benefit from early surgery before becoming symptomatic. Clinical Neurology and Neurosurgery, 2013, 115, 2514-2520.	1.4	25
78	Biological and radiological exploration and management of non-functioning pituitary adenoma. Annales D'Endocrinologie, 2015, 76, 201-209.	1.4	25
79	SST5 expression and USP8 mutation in functioning and silent corticotroph pituitary tumors. Endocrine Connections, 2020, 9, 243-253.	1.9	25
80	Is Gross Total Resection Reasonable in Adults with Craniopharyngiomas with Hypothalamic Involvement?. World Neurosurgery, 2019, 129, e803-e811.	1.3	24
81	Immune Landscape of Pituitary Tumors Reveals Association Between Macrophages and Gonadotroph Tumor Invasion. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3459-3473.	3.6	23
82	Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2022, 10, 102-111.	11.4	23
83	Consensus statement by the French Society of Endocrinology (SFE) and French Society of Pediatric Endocrinology & Diabetology (SFEDP) on diagnosis of Cushing's syndrome. Annales D'Endocrinologie, 2022, 83, 119-141.	1.4	23
84	Aggressive prolactinomas: how to manage?. Pituitary, 2020, 23, 70-77.	2.9	22
85	Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs. Frontiers in Endocrinology, 2019, 10, 931.	3.5	21
86	Gravesâ€™ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review). Cancers, 2021, 13, 1944.	3.7	21
87	Chromosomal instability in the prediction of pituitary neuroendocrine tumors prognosis. Acta Neuropathologica Communications, 2020, 8, 190.	5.2	20
88	Confirmation of a new therapeutic option for aggressive or dopamine agonist-resistant prolactin pituitary neuroendocrine tumors. European Journal of Endocrinology, 2019, 181, C1-C3.	3.7	20
89	Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review. Endocrine-Related Cancer, 2022, 29, 415-426.	3.1	20
90	Aggressive corticotroph tumors and carcinomas. Journal of Neuroendocrinology, 2022, 34, .	2.6	20

#	Article	IF	Citations
91	X-Linked Sex-Determining Region Y Box 3 (SOX3) Gene Mutations Are Uncommon in Men with Idiopathic Oligoazoospermic Infertility. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4146-4148.	3.6	19
92	Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors. Molecular Cancer Therapeutics, 2016, 15, 1261-1270.	4.1	19
93	Transdifferentiation of Neuroendocrine Cells. American Journal of Surgical Pathology, 2017, 41, 849-853.	3.7	19
94	MANAGEMENT OF ENDOCRINE DISEASE Hyperandrogenic states in women: pitfalls in laboratory diagnosis. European Journal of Endocrinology, 2018, 178, R141-R154.	3.7	19
95	Identification of predictive criteria for pathogenic variants of primary bilateral macronodular adrenal hyperplasia (PBMAH) gene ARMC5 in 352 unselected patients. European Journal of Endocrinology, 2022, 187, 123-134.	3.7	18
96	18F-FDG PET/CT Findings in a Patient With Isolated Intracranial Rosai-Dorfman Disease. Clinical Nuclear Medicine, 2013, 38, e50-e52.	1.3	17
97	Bilateral adrenalectomy in Cushing's disease: Altered long-term quality of life compared to other treatment options. Annales D'Endocrinologie, 2019, 80, 32-37.	1.4	17
98	Gonadotroph Tumors Show Subtype Differences that Might Have Implications for Therapy. Cancers, 2020, 12, 1012.	3.7	17
99	Dilated Cardiomyopathy Revealing Cushing Disease. Medicine (United States), 2015, 94, e2011.	1.0	16
100	Silent GH pituitary tumor: Diagnostic and therapeutic challenges. Annales D'Endocrinologie, 2013, 74, 491-495.	1.4	15
101	Illicit Upregulation of Serotonin Signaling Pathway in Adrenals of Patients With High Plasma or Intra-Adrenal ACTH Levels. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4967-4980.	3.6	15
102	Treatment Options for Gonadotroph Tumors: Current State and Perspectives. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3507-e3518.	3.6	15
103	Risks and Benefits of Endoscopic Transsphenoidal Surgery for Nonfunctioning Pituitary Adenomas in Patients of the Ninth Decade. World Neurosurgery, 2017, 106, 315-321.	1.3	14
104	Pathological markers of somatotroph pituitary neuroendocrine tumors predicting the response to medical treatment. Minerva Endocrinologica, 2019, 44, 129-136.	1.8	14
105	Neoadjuvant B-RAF and MEK Inhibitor Targeted Therapy for Adult Papillary Craniopharyngiomas: A New Treatment Paradigm. Frontiers in Endocrinology, 0, 13, .	3.5	14
106	Somatostatin receptor ligands induce TSH deficiency in thyrotropin-secreting pituitary adenoma. European Journal of Endocrinology, 2021, 184, 1-8.	3.7	13
107	Clinicopathological prognostic and theranostic markers in pituitary tumors. Minerva Endocrinologica, 2016, 41, 377-89.	1.8	12
108	Second line treatment of acromegaly: Pasireotide or Pegvisomant?. Best Practice and Research in Clinical Endocrinology and Metabolism, 2022, 36, 101684.	4.7	11

#	Article	IF	Citations
109	ALK7 expression in prolactinoma is associated with reduced prolactin and increased proliferation. Endocrine-Related Cancer, 2018, 25, 795-806.	3.1	10
110	Prolactin immunoassay: does the high-dose hook effect still exist?. Pituitary, 2022, 25, 653-657.	2.9	10
111	Macroprolactinaemia: a biological diagnostic strategy from the study of 222 patients. European Journal of Endocrinology, 2015, 172, 687-695.	3.7	9
112	Therapeutic innovations in endocrine diseases â€“ partÂ3Â: temozolomide and future therapeutics for aggressive pituitary tumors and carcinomas. Presse Medicale, 2016, 45, e211-e216.	1.9	9
113	Diagnosis, pathology, and management of TSH-secreting pituitary tumors. A single-center retrospective study of 20Âpatients from 1981 to 2014. Annales D'Endocrinologie, 2019, 80, 216-224.	1.4	9
114	Evolution of macroprolactinomas during pregnancy: A cohort study of 85 pregnancies. Clinical Endocrinology, 2020, 92, 421-427.	2.4	9
115	Modern neuro-ophthalmological evaluation of patients with pituitary disorders. Best Practice and Research in Clinical Endocrinology and Metabolism, 2019, 33, 101279.	4.7	8
116	Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study. Endocrine, 2021, 71, 158-167.	2.3	8
117	Cabergoline in severe ectopic or occult Cushingâ€™s syndrome. European Journal of Endocrinology, 2019, 181, K1-K9.	3.7	8
118	Efficacy and safety of dopamine agonists in patients treated with antipsychotics and presenting a macroprolactinoma. European Journal of Endocrinology, 2020, 183, 221-231.	3.7	8
119	Performance of the 4-mg intravenous dexamethasone suppression test in differentiating Cushing disease from pseudo-Cushing syndrome. Annales D'Endocrinologie, 2016, 77, 30-36.	1.4	7
120	Reconsidering olfactory bulb magnetic resonance patterns in Kallmann syndrome. Annales D'Endocrinologie, 2017, 78, 455-461.	1.4	7
121	A key role for conservative treatment in the management of pituitary apoplexy. Endocrine, 2021, 71, 168-177.	2.3	7
122	Pituitary Society Delphi Survey: An international perspective on endocrine management of patients undergoing transsphenoidal surgery for pituitary adenomas. Pituitary, 2022, 25, 64-73.	2.9	7
123	Pituitary MRI Features in Acromegaly Resulting From Ectopic GHRH Secretion From a Neuroendocrine Tumor: Analysis of 30 Cases. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3313-e3320.	3.6	7
124	GNAS mutated thyroid carcinoma in a patient with Mc Cune Albright syndrome. Bone Reports, 2020, 13, 100299.	0.4	6
125	Pegvisomant treatment in acromegaly in clinical practice: Final results of the French ACROSTUDY (312) Tj ETQq1 1 0.784314 rgBT /O	1.4	6
126	Familial pituitary adenomas with a heterogeneous functional pattern: Clinical and genetic features. Journal of Endocrinological Investigation, 2007, 30, 787-790.	3.3	5

#	Article	IF	Citations
127	Pheochromocytoma, paragangliomas, and pituitary adenoma. Medicine (United States), 2019, 98, e16594.	1.0	5
128	Metformin and everolimus in neuroendocrine tumours: A synergic effect?. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 954-960.	1.5	5
129	Postoperative remission of non-invasive lactotroph pituitary tumor: A single-center experience. Annales D'Endocrinologie, 2022, 83, 1-8.	1.4	5
130	Intratumoural spatial distribution of S100Bâ€‰+â€‰folliculostellate cells is associated with proliferation and expression of FSH and ERÎ± in gonadotroph tumours. Acta Neuropathologica Communications, 2022, 10, 18.	5.2	5
131	UrinaryÂfree cortisol: An automated immunoassay without extraction for diagnosis of Cushingâ€™s syndrome and followâ€up of patients treated by anticortisolic drugs. Clinical Endocrinology, 2020, 93, 76-78.	2.4	4
132	Cost-Utility of Acromegaly Pharmacological Treatments in a French Context. Frontiers in Endocrinology, 2021, 12, 745843.	3.5	4
133	Ectopic acromegaly due to growth hormone-releasing hormone producing bronchial carcinoid causing somatotroph hyperplasia and partial pituitary insufficiency. Polish Archives of Internal Medicine, 2019, 129, 208-210.	0.4	4
134	Cabergoline therapy of paraneoplastic cushing syndrome in children. Pediatric Blood and Cancer, 2010, 55, 590-591.	1.5	3
135	Classification of Pituitary Neuroendocrine Tumors (PitNets). , 2019, , 176-184.		3
136	Carcinome hypophysaire. , 2010, , 441-445.		2
137	Pituitary siderosis: the dark side of the pituitary. Lancet Diabetes and Endocrinology,the, 2016, 4, 374.	11.4	2
138	Centralization errors in comparative genomic hybridization array analysis of pituitary tumor samples. Genes Chromosomes and Cancer, 2018, 57, 320-328.	2.8	2
139	Evaluation of Nursesâ€™ and Patientsâ€™ Overall Satisfaction with New and Previous Formulations of Octreotide Long-acting Release (Sandostatin LARÂ®): A French Observational Study. Advances in Therapy, 2020, 37, 3901-3915.	2.9	2
140	Physiopathology, Diagnosis, and Treatment of Nonfunctioning Pituitary Adenomas. Endocrinology, 2018, , 93-128.	0.1	1
141	Unusual neurologic presentation of aseptic abscesses syndrome. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e469.	6.0	1
142	Letter to the Editor From Helene Lasolle and GÃ©rald Raverot: â€œUSP8 and TP53 Drivers Are Associated With CNV in a Corticotroph Adenoma Cohort Enriched for Aggressive Tumorsâ€• Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3285-e3286.	3.6	1
143	Diagnosis and Clinical Management of Aggressive Pituitary Tumors. , 2019, , 294-300.		1
144	Craniopharyngioma: Endocrinological Aspects After Surgery. , 2020, , 145-156.		1

#	Article	IF	Citations
145	An old retrocardiac mass fortuitously reclassified as paraganglioma. Annales D'Endocrinologie, 2016, 77, 668-669.	1.4	0
146	Dramatic change in skin color after bilateral adrenalectomy in Cushing's disease. Annales D'Endocrinologie, 2016, 77, 623-624.	1.4	0
147	Dysregulation of cell cycle in animal models and human neuroendocrine pituitary tumors (PitNET). Cell Cycle, 2018, 17, 917-917.	2.6	0
148	35e CongrÃ¨s de la SociÃ©tÃ© franÃ§aise dâ€™endocrinologie (SFE) Nancy 2018. Annales D'Endocrinologie, 2018, 79, 191.	1.4	0
149	Management of aggressive pituitary tumors. , 2021, , 485-497.		0
150	Integrated Genomic Profiling Identifies Loss of Chromosome 11p Impacting Transcriptomic Activity in Aggressive Pituitary PRL Tumours. , 2011, , P3-69-P3-69.		0
151	Physiopathology, Diagnosis, and Treatment of Nonfunctioning Pituitary Adenomas. Endocrinology, 2018, , 1-37.	0.1	0
152	First Case of Chronic Post-Traumatic Anterior Pituitary Dysfunction in a Professional Rugby Player: A Case Report. Annales D'Endocrinologie, 2022, , .	1.4	0